Research & Innovation - Participant Portal

Search

TOPIC : Research on HIV, tuberculosis (TB) and/or hepatitis C (HCV) in patients with mono-, co-infections and/or comorbidities in the context of fostering collaboration with the Russian Federation

Topic identifier: SC1-BHC-21-2018
Publication date: 27 October 2017

Types of action: RIA Research and Innovation action
DeadlineModel:
Opening date:
single-stage
07 November 2017
Deadline: 18 April 2018 17:00:00

Time Zone : (Brussels time)
  Horizon 2020 H2020 website
Pillar: Societal Challenges
Work Programme Year: H2020-2018-2020
Topic Description
Specific Challenge:

ECDC (European Centre for Disease Control) and WHO-Europe (World Health Organisation) report high number of cases for HIV and TB infections (both in incidence and prevalence) in the European regions and in recent years the epidemic situation has deteriorated in eastern Europe[1],[2].

For TB, in particular diagnosis and treatment of multidrug-resistant TB (MDR-TB) poses a major challenge. In the east of Europe there is still high burden of TB and HIV and their comorbid forms. Additionally, a significant proportion of the infected patients are also affected by co-infections and comorbidities that may adversely affect their prognosis, which is a global challenge in healthcare and in particular refers to TB/HIV cases.

Several issues in the current epidemiological situation are still to be addressed to reduce the cases of new infections and deaths, including investigation of reasons underlying fast spread of M-DR-TB and HIV/AIDS in some regions, development of rapid tools for an accurate detection of TB infections and management of HIV and TB drug resistance. Adverse effects of treatments and the requirement for strict adherence to antiretroviral treatment further complicate management of these diseases.

Furthermore, in the WHO European Region an estimated 15 million people live with hepatitis C (2.0% of adults) with two-thirds of infected persons in the Region living in eastern Europe and central Asia[3]. Also for HCV there are many challenges, including the need to analyse genetically determined factors affecting disease progression in HCV infected patients (with mono-infection or HIV-HCV co-infection).

Given the dynamics of the epidemics and the need to contain them, there is a commitment from the European Union and from the Russian Federation to support joint research and further strengthen the collaboration between research and healthcare centres to address the issues outlined above.

Scope:

Proposals should address one or more of the following subtopics:

  1. TB: To investigate biomarkers or new diagnostic tests for early screening of TB risk groups for TB infection and identification of antimicrobial drug resistance.
  2. HIV: To investigate the susceptibility to HIV and/or disease progression rate after infection, including various HIV subtypes and/or transmission clusters, and/or the development of adverse effects during antiretroviral therapy and concomitant diseases (comorbidities and/or co-infections, including with tuberculosis).
  3. HCV: To evaluate the genetic determinants of the virus and the host, and comorbid conditions that can be involved in disease progression and create the basis for the development of future HCV treatment strategies.

In performing the research agenda to address one (or more) of the listed subtopics, the applicants might make use of already established European cohort networks or establish new collaborations thus widening their geographical scope and include HIV, HCV and/or TB mono or co-infected individuals and perform retrospective or prospective studies. Proposed actions should take into consideration vulnerable groups and target populations, which may include, but not limited to: ageing subjects, injecting drug users and other social risk groups. Sex and gender differences should be taken into account where relevant.

Due to the specific challenge of this topic, in addition to the minimum number of participants set out in the General Annexes, proposals shall include at least one participant from the Russian Federation. Also, the duration of the proposed action cannot exceed 24 months (until end of 2020), with a foreseen start of the action no later than 1 January 2019. For more information, interested entities in the Russian Federation shall consult the website of the Russian NCP for Health at http://www.h2020-health.ru/ru/competition-ru-eu, as well as the website of the Ministry of Education and Science of the Russian Federation http://www.fcpir.ru/participation_in_program/contests/list_of_contests/, where the corresponding Russian call will be published.

The Commission considers that a proposal requesting an EU contribution between EUR 2 to 3 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude the submission and selection of proposals requesting other amounts.

Expected Impact:
  • Improvement of coordination and integration between European and Russian clinical and research centres dealing with HIV, TB and/or HCV infected patients.
  • Produce scientific evidence leading in the long-term to the reduction of the burden of these infection diseases.
  • Produce scientific evidence and contribute to the optimisation (and personalisation) of diagnosis, treatments and improvement of quality of life of patients affected by HCV, HIV and/or TB infections (mono or co-infections) and comorbidities.
  • Contribute to the achievement of the Sustainable Development Goal 3: Ensure Healthy lives and promote wellbeing for all at all ages, the WHO end TB strategy[4], the WHO global health sector strategy on HIV[5] , and the WHO global health sector strategy on viral hepatitis[6].
Cross-cutting Priorities:

Gender
International cooperation

[1]http://ecdc.europa.eu/en/publications/Publications/HIV-AIDS-surveillance-Europe-2015.pdf

[2]http://ecdc.europa.eu/en/publications/Publications/tuberculosis-surveillance-monitoring-Europe-2015.pdf

[3]http://www.euro.who.int/en/health-topics/communicable-diseases/hepatitis/data-and-statistics

[4]http://www.who.int/tb/strategy/end-tb/en/

[5]http://www.who.int/hiv/strategy2016-2021/ghss-hiv/en/

[6]http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/

Topic conditions and documents

1. Eligible countries: described in Annex A of the Work Programme.
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon 2020 projects. See the information in the Online Manual.

2. Eligibility and admissibility conditions: described in Annex B and Annex C of the Work Programme.

Due to the specific challenge of this topic, in addition to the minimum number of participants set out in the General Annexes, proposals shall include at least one participant from the Russian Federation.

Proposal page limits and layout: please refer to Part B of the proposal template in the submission system below.

3. Evaluation:

  • Evaluation criteria, scoring and thresholds are described in Annex H of the Work Programme.
  • Submission and evaluation processes are described in the Online Manual.

The thresholds for each criterion in a single stage process will be 4, 4 and 3. The cumulative threshold will be 12.
The same applies to the second stage of the two-stage call for topics SC1-BHC15-2018, SC1-BHC01-2019, SC1-BHC02-2019, SC1-BHC14-2019, SC1-BHC19-2019, SC1-BHC22-2019, SC1-BHC25-2019

4. Indicative time for evaluation and grant agreements:

Information on the outcome of evaluation (single-stage call): maximum 5 months from the deadline for submission.
Signature of grant agreements: maximum 8 months from the deadline for submission.

5. Proposal templates, evaluation forms and model grant agreements (MGA):

Research and Innovation Action:

Specific provisions and funding rates
Standard proposal template
Standard evaluation form
General MGA - Multi-Beneficiary
Annotated Grant Agreement

Essential information for clinical studies

6. Additional provisions:

Horizon 2020 budget flexibility
Classified information
Technology readiness levels (TRL) – where a topic description refers to TRL, these definitions apply.

Members of consortium are required to conclude a consortium agreement, in principle prior to the signature of the grant agreement.

7. Open access must be granted to all scientific publications resulting from Horizon 2020 actions.

Where relevant, proposals should also provide information on how the participants will manage the research data generated and/or collected during the project, such as details on what types of data the project will generate, whether and how this data will be exploited or made accessible for verification and re-use, and how it will be curated and preserved.

Open access to research data
The Open Research Data Pilot has been extended to cover all Horizon 2020 topics for which the submission is opened on 26 July 2016 or later. Projects funded under this topic will therefore by default provide open access to the research data they generate, except if they decide to opt-out under the conditions described in Annex L of the Work Programme. Projects can opt-out at any stage, that is both before and after the grant signature.

Note that the evaluation phase proposals will not be evaluated more favourably because they plan to open or share their data, and will not be penalised for opting out.

Open research data sharing applies to the data needed to validate the results presented in scientific publications. Additionally, projects can choose to make other data available open access and need to describe their approach in a Data Management Plan.

Projects need to create a Data Management Plan (DMP), except if they opt-out of making their research data open access. A first version of the DMP must be provided as an early deliverable within six months of the project and should be updated during the project as appropriate. The Commission already provides guidance documents, including a template for DMPs. See the Online Manual.

Eligibility of costs: costs related to data management and data sharing are eligible for reimbursement during the project duration.

The legal requirements for projects participating in this pilot are in the article 29.3 of the Model Grant Agreement.

8. Additional documents:

Introduction WP 2018-20
Health, demographic change and well-being WP 2018-20
General annexes to the Work Programme 2018-2020

Legal basis: Horizon 2020 Regulation of Establishment
Legal basis: Horizon 2020 Rules for Participation
Legal basis: Horizon 2020 Specific Programme

Submission Service

To access the Electronic Submission Service of the topic, please select the type of action that is most relevant to your proposal from the list below and click on the 'Start Submission' button. You will then be asked to confirm your choice of the type of action and topic, as these cannot be changed in the submission system. Upon confirmation you will be linked to the correct entry point.

To access existing draft proposals for this topic, please login to the Participant Portal and select the My Proposals page of the My Area section.

Type of Action Research and Innovation action [RIA]
Topic Research on HIV, tuberculosis (TB) and/or hepatitis C (HCV) in patients with mono-, co-infections and/or comorbidities in the context of fostering collaboration with the Russian Federation - SC1-BHC-21-2018
Guidance on proposal submission: H2020 online manual
IT Guidance: IT help

Get support

H2020 Online Manual is your guide on the procedures from proposal submission to managing your grant.

Participant Portal FAQ – Submission of proposals.

National Contact Points (NCP) - contact your NCP for further assistance in your national language(s).

Research Enquiry Service – ask questions about any aspect of European research in general and the EU Research Framework Programmes in particular.

Enterprise Europe Network – contact your EEN national contact for advice to businesses with special focus on SMEs. The support includes guidance on the EU research funding.

IT Helpdesk - contact the Participant Portal IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.

Ethics – for compliance with ethical issues, see the Online Manual and Science and Society Portal

European IPR Helpdesk assists you on intellectual property issues

CEN and CENELEC, the European Standards Organisations, advise you how to tackle standardisation in your project proposal. Contact CEN-CENELEC Research Helpdesk at research@cencenelec.eu

The European Charter for Researchers and the Code of Conduct for their recruitment

Partner Search Services help you find a partner organisation for your proposal.